Who are RBV(48 weeks)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Veklury, RIFAMPIN, Ribavirin, Peg interferon alfa 2b, Ribavirin in Arm 1, Rifampicin (R), Rifamycin-containing regimen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rbv-48-weeks.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

RBV(48 weeks) — Competitive Intelligence Brief

RBV(48 weeks) (RBV(48 weeks)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog. Area: Infectious Diseases.

phase 3 Nucleoside analog RNA polymerase Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

RBV(48 weeks) (RBV(48 weeks)) — Tanabe Pharma Corporation. Ribavirin is an antiviral medication that works by inhibiting viral RNA synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RBV(48 weeks) TARGET	RBV(48 weeks)	Tanabe Pharma Corporation	phase 3	Nucleoside analog	RNA polymerase
Veklury	remdesivir	Gilead Sciences	marketed	Nucleotide analog RNA polymerase inhibitor	SARS-CoV-2 RNA polymerase	2020-01-01
RIFAMPIN	RIFAMPIN		marketed	Rifamycin Antibacterial [EPC]	DNA-dependent RNA polymerase	1971-01-01
Ribavirin, Peg interferon alfa 2b	Ribavirin, Peg interferon alfa 2b	Brooke Army Medical Center	marketed	Antiviral combination therapy	HCV RNA-dependent RNA polymerase; interferon-alpha receptor
Ribavirin in Arm 1	Ribavirin in Arm 1	MinaPharm Pharmaceuticals	marketed	Nucleoside analog antiviral	Viral RNA polymerase; IMPDH (inosine monophosphate dehydrogenase)
Rifampicin (R)	Rifampicin (R)	University College, London	marketed	Rifamycin antibiotic	Bacterial RNA polymerase β-subunit
Rifamycin-containing regimen	Rifamycin-containing regimen	National Taiwan University Hospital	marketed	Rifamycin antibiotic	Bacterial RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analog class)

Third Affiliated Hospital, Sun Yat-Sen University · 2 drugs in this class
Actuate Therapeutics Inc. · 2 drugs in this class
City of Hope Medical Center · 1 drug in this class
Cooperative Study Group A for Hematology · 1 drug in this class
Genzyme, a Sanofi Company · 1 drug in this class
Hospices Civils de Lyon · 1 drug in this class
Innovent Biologics (Suzhou) Co. Ltd. · 1 drug in this class
Osaka Medical Center for Cancer and Cardiovascular Diseases · 1 drug in this class
Tanabe Pharma Corporation · 1 drug in this class
The Methodist Hospital Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RBV(48 weeks) — Competitive Intelligence Brief. https://druglandscape.com/ci/rbv-48-weeks. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab